Oxytocin: Research Applications

Aplicacoes de Pesquisa

Oxytocin research spans obstetrics, neuropsychiatry, metabolic disease, and cardiovascular health with extensive clinical and predados clinicos across 5+ indication categories:

1. Labor Induction & PPH — Primary authorized indication; carbetocin comparisons show lower blood loss (Pathak 2025: 362.5 vs 392.9 mL, p=0.00004).[4]
2. Autism Spectrum Disorder — Meta-analysis of 12 RCTs (n=498): 48 IU/day optimal dose (SMD = -1.13); inverted-U dose-response. Large trial (Sikich 2021, NEJM) showed no significant benefit at standard doses.[7][8]
3. Obesity & Metabolism — Plessow 2024 (NEJM Evidence): Failed weight primary but reduziu caloric intake -152 kcal/meal. Espinoza 2021: Sarcopenic obesidade pilot → lean mass +2.25 kg, LDL -19.3 mg/dL.[9][10]
4. Neuropsychiatric Disorders — Schizophrenia, anxiety, BPD; modula amygdala activity, reduz fear responses; context-dependent in BPD (may exacerbate hypermentalization).[11]
5. Protecao Cardiovascular — ANP release, NO-mediated vasodilatacao, anti-inflamatorio(a) in aterosclerose; Petersson 1996: 21 mmHg SBP reduction in SHR rats.[6][12]
6. Prader-Willi Syndrome — CARE-PWS Phase 3: Carbetocin reduziu hyperphagia at 3.2 mg but NOT at 9.6 mg; Hollander 2021: 16 IU × 8 wk → melhorou hyperphagia/repetitive behaviors.[13]
7. Addiction & Substance Use — Opioid/alcohol/stimulant craving reduction via nucleus accumbens reward circuitry modulacao.[3]
8. Pain Management — Positive allosteric modulator of mu-opioid receptors; spinal nociceptive inibicao.[3]
9. Sarcopenia & Aging — OXT necessario(a) para muscle stem cell regeneration; Oxt-/- mice develop premature sarcopenia/osteoporose, reversible with OXT.[14]
10. Postpartum Depression — Observational (n=904): synOT during labor → PPD rate 21% vs 37% sem (p<0.001).[15]